Vaccination against hepatitis B in patients with chronic liver disease

被引：0

作者：

Reiss G. ^{[1
]}

Keeffe E.B. ^{[1
]}

机构：

[1] Stanford University Medical Center, Palo Alto, CA 94304-1509

来源：

Current Hepatitis Reports | 2006年 / 5卷 / 2期

关键词：

Chronic Liver Disease; Fulminant Hepatitis; Hepatitis Delta Virus; Chronic Coinfection;

D O I：

10.1007/s11901-006-0005-0

中图分类号：

学科分类号：

摘要：

The prevalence of chronic liver disease is increasing, while at the same time, many at-risk populations are witnessing a resurgence of hepatitis B virus (HBV) infection. Thus, more patients are likely to have multiple causes of liver disease, as risk factors often overlap. Such patients may develop either acute viral hepatitis superimposed on pre-existing chronic liver disease or chronic infection with two hepatitis viruses. Patients with chronic HBV and hepatitis C virus coinfection have more severe laboratory abnormalities, more hepatic fibrosis, and greater frequency of cirrhosis, in addition to more complications of cirrhosis and a higher incidence of hepatocellular carcinoma. Acute hepatitis B superimposed on chronic hepatitis C may result in fulminant hepatitis, although this outcome is not as well proven as the increased morbidity of chronic hepatitis B and C coinfection. Both acute and chronic coinfection with HBV can be prevented. Vaccines for hepatitis B are safe in patients with chronic liver disease of a variety of causes and are effective, particularly if used early. Early vaccination against hepatitis B, as well as hepatitis A, should be part of the routine management of chronic liver disease. Copyright © 2006 by Current Science Inc.

引用

页码：58 / 62

页数：4

共 35 条

[21]

Ilan Y., Ashur Y., Tur-Kaspa R., Shouval D., Chronic hepatitis C virus infection with exposure to hepatitis B virus, Isr J Med Sci, 30, pp. 259-263, (1994)

[22]

Law D.T., Hewlett A.T., Screening for hepatitis A and B antibodies in patients with chronic liver disease, Am J Med, 118, pp. 285-335, (2005)

[23]

Berger A., Doerr H.W., Rabenau H.F., Weber B., High frequency of HCV infection in individuals with isolated antibody to hepatitis B core antigen, Intervirology, 43, pp. 71-76, (2000)

[24]

Weber B., Melchior W., Gehrke R., Et al., Hepatitis B virus markers in anti-HBc only positive individuals, J Med Virol, 64, pp. 312-319, (2001)

[25]

McMahon B.J., Parkinson A.J., Helminiak C., Et al., Response to hepatitis B vaccine of persons positive for antibody to hepatitis B core antigen, Gastroenterology, 103, pp. 590-594, (1992)

[26]

Chlabicz S., Grzeszczuk A., Hepatitis B virus vaccine for patients with hepatitis C virus infection, Infection, 28, pp. 341-345, (2000)

[27]

Rosman A.S., Basu P., Galvin K., Lieber C.S., Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: A randomized clinical trial, Am J Med, 103, pp. 217-222, (1997)

[28]

Beran J., Dedek P., Stepanova V., Et al., Safety and immunogenicity of a combined vaccine against hepatitis A and B in patients with autoimmune hepatitis, Cent Eur J Public Health, 13, pp. 20-23, (2005)

[29]

Mattos A.A., Gomes E.B., Tovo C.V., Et al., Hepatitis B vaccine efficacy in patients with chronic liver disease by hepatitis C virus, Arq Gastroenterol, 41, pp. 180-184, (2004)

[30]

Villeneuve E., Vincelette I., Villeneuve J.P., Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation, Can J Gastroenterol, 14, SUPPL. B, (2000)

← 1 2 3 4 →